Marico’s domestic revenue increased 23% YoY, along with growth in volumes by 7% YoY (marginally lower vs our estimate of 8%). International sales grew 10.7% YoY (16% YoY in constant currency terms). Consolidated revenue increased 19.8% YoY to Rs 27.3 billion, in line with our estimate of Rs 26.9 billion. Consolidated gross margin came in at 48.6% (lower than our est. of 49.8%; down by 300 bps YoY and 90 bps QoQ), mainly impacted by the rising trend in copra and vegetable oil prices, which was only partly offset by pricing interventions in key portfolios.
Marico’s domestic revenue increased 23% YoY, along with growth in volumes by 7% YoY (marginally lower vs our estimate of 8%). International sales grew 10.7% YoY (16% YoY in constant currency terms). Consolidated revenue increased 19.8% YoY to Rs 27.3 billion, in line with our estimate of Rs 26.9 billion. Consolidated gross margin came in at 48.6% (lower than our est. of 49.8%; down by 300 bps YoY and 90 bps QoQ), mainly impacted by the rising trend in copra and vegetable oil prices, which was only partly offset by pricing interventions in key portfolios.
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
While Marico Ltd. reported largely in line set of numbers across all key line items in its Q4 FY25 results, the sharp 48% YoY increase in copra prices is likely to dent operating margins in H1 FY26. Thus, while the management is targeting double digit sales growth in FY26 and aspiring for double digit profitability growth as well, achieving the latter could be challenging, in our view.
Growth businesses (foods and premium personal care) are largely on track on sales growth expectations and profitability.
We expect EPS CAGR of 12.7% over FY25-FY27E, broadly in line with the EPS CAGR of ~11% over 10 years. Valuing the company at 45 times FY27E EPS (in line with the 10-year average multiple), we get a marginal upside of ~3% to the current market price. We maintain Hold rating as we await a better entry point.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU

'Hold' Sagar Cements Shares Retains Nirmal Bang — Here's Why


Nirmal Bang Maintains 'Hold' On Mankind Pharma Shares, Revises Target Price — Here's Why


Shriram Finance Shares: Nirmal Bang Maintains 'Hold' Rating; Expects Steady AUM Growth In FY26


'Buy' Sun Pharma Shares Maintains Nirmal Bang, Says India, Specialty To Drive Growth
